New dosing schedule could ease sickle cell treatment for kids
NCT ID NCT06578507
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing whether giving hydroxyurea twice a day works better than the usual once-daily dose for children with sickle cell disease. About 50 children aged 9 months to 11 years will take the drug for 12 months. Researchers will measure how the drug behaves in the body and whether it helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydroxyurea (hydroxycarbamide) dispersible tablets
What this could lead to
If successful, this could offer a more convenient twice-daily dosing option for children with sickle cell disease, potentially improving adherence and disease control.
What could go wrong
This is a small, early-phase study with only 50 children and no comparison group. It may not show clear benefits, and side effects like bone marrow suppression are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Centre Hospitalier Intercommunal Créteil
RECRUITINGCréteil, France
Contact
Contact
-
Centre hospitalier de Cayenne
RECRUITINGCayenne, French Guiana
Contact
Contact
-
GHEF- Site de Marne-la-Vallée
RECRUITINGJossigny, France
Contact Email: •••••@•••••
-
Hôpital Bicêtre
RECRUITINGLe Kremlin-Bicêtre, France
Contact
Contact
-
Hôpital Necker-Enfants malades
RECRUITINGParis, France
Contact
Contact
-
Institut d'Hématologie et d'oncologie pédiatrique - IHOPe
ACTIVE_NOT_RECRUITINGLyon, France